Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial - Top-Institutions - MDSpire

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

  • By

  • Ignacio Melero

  • Bernhard Reis

  • Corinne Rusterholz

  • Alexandra Epp

  • Nicole A. Kratochwil

  • Chun Wu

  • Michael Hettich

  • Georgios Kazantzidis

  • Natascha Rieder

  • Petra C. Schwalie

  • Solveig Badillo

  • Nadine Kumpesa

  • Andreas Thommen

  • Danielle J. Vugts

  • Victor Moreno

  • Julia Lostes Bardaji

  • Eduardo Castanon Alvarez

  • Carlos E. de Andrea

  • Iben Spanggaard

  • Dae Ho Lee

  • James Spicer

  • Fiona Thistlethwaite

  • Do-Youn Oh

  • Antoine Hollebecque

  • Olivera Cirovic

  • Stefan N. Symeonides

  • May 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

  • #2

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, FL

    Key Differentiators

    • Oncology

  • #3

    The Ohio State University Comprehensive Cancer Center
    The Ohio State University Comprehensive Cancer Center

    Columbus, OH

    Key Differentiators

    • Oncology

  • #4

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Oncology

Original Source(s)

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

  • by Ignacio Melero, Bernhard Reis, Corinne Rusterholz, Alexandra Epp, Nicole A. Kratochwil, Chun Wu, Michael Hettich, Georgios Kazantzidis, Natascha Rieder, Petra C. Schwalie, Solveig Badillo, Nadine Kumpesa, Andreas Thommen, Danielle J. Vugts, Victor Moreno, Julia Lostes Bardaji, Eduardo Castanon Alvarez, Carlos E. de Andrea, Iben Spanggaard, Dae Ho Lee, James Spicer, Fiona Thistlethwaite, Do-Youn Oh, Antoine Hollebecque, Olivera Cirovic, Stefan N. Symeonides

  • May 1, 2026

Related Content

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer